Marco Boorsma
General Partner at Forbion
Amsterdam Area
Overview
Work Experience
General Partner
2017 - Current
Partner
2014 - 2017
Principal
2010 - 2014
Senior Analyst
2007 - 2010
Board Director at Calluna Pharma
2024
Board Director at Sitala
2021
Board Director at Rectify Pharma
2021
Rectify Pharmaceuticals is a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics.
Raised $100,000,000.00 from Forbion Capital Partners, Longwood Fund, Omega Funds and Atlas Venture.
Board Director at VectorY
2021
VectorY develops innovative vectorized antibody gene therapies
Chief Executive Officer
2020 - 2021
VectorY is a fully integrated gene therapy company focused on the development of innovative therapeutics such as vectorized antibodies for both CNS and somatic disorders, with a special focus on muscle diseases.
Chairman of the Board
2020 - 2023
Oxitope Pharma was merged with Arxx Therapeutics into Calluna Pharma
Board Director at enGene
2017 - 2023
EnGene (Nasdaq: ENGN) develops non-viral gene therapies targeting mucosal tissues. Lead program is in pivotal clinical studies in NMIBC
Board Director at Inversago
2020 - 2023
Inversago develops peripherally acting CB1 inhibitors for treatment of metabolic and inflammatory diseases. Inversago was acquired by Novo Nordisk
Board Director at Escalier Biosciences
2018 - 2023
Escalier develops novel therapeutics to treat autoimmune diseases
Escalier Biosciences BV is a privately held biopharmaceutical company.
Raised $19,000,000.00 from BioGeneration Ventures, New Science Ventures and Forbion Capital Partners.
Board Director at Inflazome
2018 - 2020
Inflazome was acquired by Roche